Through its potent ability to downregulate NGF expression in Panc-1 cells and pancreatic tumors, the GNC–siRNA complex has proven to be an effective inhibitor of tumor progression in three different pancreatic tumor models (including subcutaneous, orthotopic, and patient-derived xenograft models), all without any negative side effects. This evidence concerns the gene NGF and pancreatic neoplasm.